E3 PreliminaryPreliminaryPEM unclearReview-NarrativePeer-reviewedMachine draft
Human herpesvirus-6 (HHV-6) (short review).
Ablashi, D V, Salahuddin, S Z, Josephs, S F et al. · In vivo (Athens, Greece) · 1991
Quick Summary
This review examines Human Herpesvirus-6 (HHV-6), a common virus that most people carry. The virus can reactivate in people with certain illnesses, including ME/CFS. The study found that people with ME/CFS sometimes have higher levels of antibodies to HHV-6, suggesting the virus may be active in their bodies.
Why It Matters
This review provides important background on a virus that some ME/CFS researchers have investigated as a potential contributor to disease. Understanding HHV-6 reactivation patterns in ME/CFS could help explain immune dysfunction and inform future treatment strategies. The observation that ME/CFS patients show elevated HHV-6 antibodies suggests viral reactivation warrants further investigation as a disease mechanism.
Observed Findings
- Approximately 80% of the general population carries HHV-6 antibodies (measured by IFA at titers ≥1:80)
- HHV-6 reactivation occurs in ME/CFS patients, as well as in malignant, non-malignant, and immunocompromised populations
- Elevated HHV-6 antibody titers were observed in lymphoproliferative disorders, autoimmune diseases, and HIV-positive patients
- Strain variability exists in HHV-6 isolates, with GS prototype showing resistance to acyclovir and gancyclovir
- Genomic homology identified between HHV-6 and HHV-7 through restriction analysis
Inferred Conclusions
- HHV-6 reactivation is associated with various disease states including ME/CFS, suggesting immune dysregulation may permit viral reactivation
- Strain-dependent antiviral susceptibility may complicate treatment approaches in HHV-6-associated conditions
- HHV-6 and HHV-7 share sufficient genomic homology to suggest related biological properties and evolutionary origins
Remaining Questions
- What proportion of ME/CFS patients specifically show HHV-6 reactivation, and how do antibody titers correlate with symptom severity?
- Does HHV-6 reactivation directly cause ME/CFS symptoms or is it a marker of underlying immune dysfunction?
What This Study Does Not Prove
This review does not establish that HHV-6 causes ME/CFS, only that reactivation occurs in some ME/CFS patients. It does not demonstrate the mechanism by which HHV-6 reactivation contributes to symptom severity or whether treating HHV-6 improves outcomes. The study is observational and cannot prove causation or determine whether HHV-6 reactivation is a primary driver or secondary consequence of ME/CFS pathology.
Tags
Symptom:Fatigue
Biomarker:AutoantibodiesBlood Biomarker
Phenotype:Infection-Triggered
Method Flag:Exploratory Only
Metadata
- PMID
- 1654146
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →